A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT04958265 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Atypical Hemolytic Uremic Syndrome

Interventions

DRUG: Crovalimab

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]